Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — AusBiotech Invest (October 2019)
13 slides from Kazia Therapeutics's conference presentation, Oct 31, 2019
Slide 1: Presentation to AusBiotech Invest
A company developing innovative, high-impact drugs for cancer Presentation to AusBiotech Invest Dr James Garner Chief Executive Officer Melbourne, Australia31 October 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Rationale
Investment Rationale Our lead program, GDC-0084, was designed by Genentech, the world’s most successful cancer drug developer, and has completed a successful phase 1 human trial, showing it to be generally safe and providing signals of efficacy Company is well-financed, following a recent institutio
Slide 4: Six ongoing clinical trials across two assets, lead program covers full range of brain cancers
Six ongoing clinical trials across two assets, lead program covers full range of brain cancers Glioblastoma Most common and most aggressive brain tumour Phase II NCT03522298 DIPG Highly aggressive childhood brain tumour Phase I NCT03696355 Brain Metastases Cancer that has spread from any primary tum
Slide 5: Kazia has delivered all milestones to date, with multiple data read-outs expected over 6-12 months
Kazia has delivered all milestones to date, with multiple data read-outs expected over 6-12 months GDC-0084 Brain Cancer Cantrixil Ovarian Cancer Initial phase 1 data (dose escalation) presented at AACR Completion of recruitment to phase 1 (expansion cohort) ü Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 Comme
Slide 6: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 7: Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases
Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 Note: Temozolomide is only approved therapy for newly-diagnosed patients; Avastin (bevacizumab) is approved for use in recurrent settin
Slide 8: PI3K class is well-validated, but GDC-0084 is unique in its ability to cross the blood-brain barrier
PI3K class is well-validated, but GDC-0084 is unique in its ability to cross the blood-brain barrier FDA Approved July 2014 (blood cancers) [accelerated approval] FDA Approved September 2017 (blood cancers) [accelerated approval] FDA Approved October 2018 (blood cancers) [accelerated approval] ü ü ü
Slide 9: In GDC-0084 phase 1, patients showed a 'metabolic partial response' on FDG-PET
In GDC-0084 phase 1, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084
Slide 10: Brain cancer represents a significant commercial opportunity for GDC-0084, with limited competition
Brain cancer represents a significant commercial opportunity for GDC-0084, with limited competition ~$1.5B+ market opportunity INDICATIVE Glioblastoma 12,500 patients p.a. in the US Brain Metastases (secondary brain cancer) Childhood Brain Cancers Other Adult Primary Brain Cancers Other Cancers with
Slide 11: Recent institutional placement leaves the company well funded for next round of data read-outs
Recent institutional placement leaves the company well funded for next round of data read-outs Market Capitalisation ~AU$ 30 million Listing NASDAQ: KZIA (1:10 ratio) ASX: KZA Share Price (AU$) KZA Current Assets$7.5 million (30 June 2019) Institutional Placement$4.0 million (October 2019) Funded fo
Slide 12: Investment Rationale
Investment Rationale Our lead program, GDC-0084, was designed by Genentech, the world’s most successful cancer drug developer, and has completed a successful phase 1 human trial, showing it to be generally safe and providing signals of efficacy Company is well-financed, following a recent institutio
Slide 13: www.kaziatherapeutics.com
www.kaziatherapeutics.com
Kazia Therapeutics — AusBiotech Invest (October 2019) on 6ix